In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis.
The in vitro activity of BAY v 3522, a new orally absorbed cephalosporin, was assessed against 150 clinical isolates each of Haemophilus influenzae and Branhamella catarrhalis. The MIC90S for beta-lactamase-positive and -negative strains of H. influenzae were 8 and 2 micrograms/ml, respectively. For beta-lactamase-positive and -negative strains of B. catarrhalis, the BAY v 3522 MIC90S were 4 and 0.25 micrograms/ml, respectively. In general, BAY v 3522 was less active against H. influenzae than amoxicillin/clavulanic acid and cefixime, equivalent in activity to cefuroxime, and more active than cefaclor. BAY v 3522 had activity most similar to cefuroxime and cefaclor for B. catarrhalis but was less active than amoxicillin/clavulanic acid and cefixime.
Doern
G V
GV
Department of Clinical Microbiology, University of Massachusetts Medical Center, Worcester 01655.
Tubert
T A
TA
D000284:Administration, Oral; D000658:Amoxicillin / Q000494:pharmacology; D019980:Amoxicillin-Potassium Clavulanate Combination; D000667:Ampicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D052160:Benzothiazoles; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology*; D002969:Clavulanic Acids / Q000494:pharmacology; D004359:Drug Therapy, Combination / Q000494:pharmacology; D006193:Haemophilus influenzae / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects* / Q000201:enzymology; D010406:Penicillins / Q000494:pharmacology; D001618:beta-Lactamases / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D052160:Benzothiazoles; D002511:Cephalosporins; D002969:Clavulanic Acids; D010406:Penicillins; C064738:Bay v 3522; D019980:Amoxicillin-Potassium Clavulanate Combination; D000667:Ampicillin; D000658:Amoxicillin; D001618:beta-Lactamases